Brooks Laboratories Ltd
Brooks Laboratories Ltd Share Price Today: Live Updates & Key Insights
Get insights on Brooks Laboratories Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Brooks Laboratories Ltd Share Price Chart
BROOKS at 10 Jul 2026 06:06 PM Pharmaceuticals
70.44 -0.07(-0.10%)
Lowest Today 67.00
Highest Today 72.00
Today's Open 72.00
Prev. Close 70.51
52 Week High 164.02
52 Week Low 36.30
Brooks Laboratories Ltd Fundamentals
Traded Volume: 59,356
Market Cap(Cr): 207.50
Avg Traded Price 69.03
1 Year return -51.67%
Upper Circuit 72
Lower Circuit 67
P/E TTM 8.00
P/B Ratio 1.693
Traded Value(Cr) 41.81
EPS TTM 8.346
Book value/Share 41.640
Dividend Yield 1Y 0.00%
Brooks Laboratories Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Brooks Laboratories Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Brooks Laboratories Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -7.21%
1M +3.24%
3M -1.58%
1Y -51.67%
YTD -9.17%
Brooks Laboratories Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Brooks Laboratories Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 28858.00
Day Before Yesterday 35860.00
1W Avg 34534.00
1M Avg 35813.38
3M Avg 69568.41
Brooks Laboratories Ltd Technical Details
Brooks Laboratories Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 68
Support 2 65
Support 3 63
Pivot Point : 70
Resistance 1 73
Resistance 2 75
Resistance 3 78
Brooks Laboratories Ltd Corporate Actions
Brooks Laboratories Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Brooks Laboratories Ltd’s capital allocation strategies.
All
Ex-Date 28-Jul-2023 Type R Description /share@1:16% Record Date 28-Jul-2023 Ratio 1:16
Ex-Date 11-Feb-2020 Type R Description /share@9:20% Record Date 12-Feb-2020 Ratio 9:20
Dividends
No Dividend has been declared by BROOKS
Bonus
No Bonus has been declared by BROOKS
Splits
No Split has been declared by BROOKS
Others
Ex-Rights Date 28-Jul-2023 Premium(Rs.) 65.00 Ratio 1:16
Ex-Rights Date 11-Feb-2020 Premium(Rs.) 10.00 Ratio 9:20
Brooks Laboratories Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Brooks Laboratories Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Brooks Laboratories Ltd's relative performance and valuation against major competitors.
Stock Name Aarey Drugs & Pharmaceuticals Ltd ₹82.83 (-2.00%) M. Cap (Cr) 2.35 1 Yr Return (%) +16.76% P/E (TTM) 51.93 PB Ratio 1.56
Stock Name Coral Laboratories Ltd ₹612.00 (+3.92%) M. Cap (Cr) 2.18 1 Yr Return (%) +4.11% P/E (TTM) 13.08 PB Ratio 1.02
Stock Name Syschem (India) Ltd ₹42.50 (-2.10%) M. Cap (Cr) 2.09 1 Yr Return (%) -7.43% P/E (TTM) 22.05 PB Ratio 1.71
Stock Name Brooks Laboratories Ltd ₹70.44 (-0.10%) M. Cap (Cr) 2.08 1 Yr Return (%) -51.67% P/E (TTM) 8.44 PB Ratio 1.69
Stock Name Sat Kartar Life Ltd ₹135.90 (+0.59%) M. Cap (Cr) 2.15 1 Yr Return (%) NaN% P/E (TTM) 12.39 PB Ratio 3.13
Stock Name Gujarat Inject (Kerala) Ltd ₹13.65 (+1.87%) M. Cap (Cr) 2.00 1 Yr Return (%) +493.48% P/E (TTM) 110.22 PB Ratio 16.88
Stock Name Kerala Ayurveda Ltd ₹165.75 (+1.59%) M. Cap (Cr) 2.15 1 Yr Return (%) -70.90% P/E (TTM) -12.05 PB Ratio 19.06
Brooks Laboratories Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Brooks Laboratories Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 9.29 Mar 2025 2.63 Mar 2024 -9.68 Mar 2023 0.56 Mar 2022 3.12
PARTICULARS Investing Activities Mar 2026 -2.92 Mar 2025 -45.14 Mar 2024 0.18 Mar 2023 -0.40 Mar 2022 1.12
PARTICULARS Financing Activities Mar 2026 0.17 Mar 2025 42.43 Mar 2024 9.60 Mar 2023 -0.22 Mar 2022 -4.22
PARTICULARS Net Cash Flow Mar 2026 6.54 Mar 2025 -0.08 Mar 2024 0.10 Mar 2023 -0.06 Mar 2022 0.02
Brooks Laboratories Ltd Shareholding Pattern
This shows the ownership breakdown of Brooks Laboratories Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 52.62%
Public 37.0%
Other Institutions 0.48%
FII N/A%
Mutual Funds 9.9%
About Brooks Laboratories Ltd
Brooks Laboratories Limited was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company is a pharmaceutical manufacturing company working on contract basis and have its own marketing team to cater the critical care segment. It offer a variety of dosage from Beta lactam Tablets, Beta lactam Dry Syrup, General Injections, Liquid Injections, Dry Powder Injections, and Eye/Ear Drops, Oncology Products, Hormonal Injections etc.The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.With roots dating back to 2002, Brooks Laboratories were established with a sole purpose of being a pioneer in the Pharmaceutical industry. Right from its inception, the company has entrenched strong foothold in the Pharmaceutical business and has successfully been a prominent part of Pharmaceutical Formulation Development, Pharmaceutical Production, Pharmaceutical Exports, etc. Starting out as Manufacturer for various Pharmaceutical products in India and abroad, over the years with sheer hard work, the Company earned its valuable name in India and abroad. The Company has a world's largest dedicated EU certified plant at Vadodara.In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (R&D) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production.In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal & Rajesh Mahajan.In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF.In August 2011, Brooks Laboratories raised money by way of Initial Public Offer Rs. 63 Crore from public. During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity.On 7 March 2017, Brooks Laboratories' world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review.The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. The company commenced production in August 2017 at Baddi Plant with almost double the capacity of previous line.The Company started production and sales at its manufacturing facility in Vadodara in 2019-20.The joint venture company, Brooks Steriscience Limited, secured approval from the USFDA for Meropenem for Injection and commenced its product supply in FY 2023.
Non Independent Executive Director / WTD
Durga Sankar Maity
Registered office Village Kishanpura, Nilagarh Road Baddi, Solan, Himachal Pradesh, 174101
FAX :91-1795-654001/02/03
Background
Incorporation Year 2002
Face Value ₹10.00
Market Lot 1
FAQs on Brooks Laboratories Ltd
How to buy Brooks Laboratories Ltd shares?
To buy Brooks Laboratories Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Brooks Laboratories Ltd?
The company has a market capitalization of ₹207.50.
What is the PE & PB ratio of Brooks Laboratories Ltd?
PE is 8 and PB is 1.693.
What is the Brooks Laboratories Ltd dividend for 2025–26?
For the 2025–26 financial year, Brooks Laboratories Ltd declared a final dividend of 0.00% per share.